Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-11-06

FDA Approved: ALECENSA — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

FDA has approved a supplemental application for Alecensa (alectinib hydrochloride) from Genentech, expanding its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Alecensa (alectinib)

Snippet

SUPPL AP for ALECENSA (ALECTINIB HYDROCHLORIDE)